Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)
Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)
Participants will receive PegIntron injection pen (Peginterferon alfa-2b) and Rebetol
 (Ribavirin) combination therapy as their usual medical treatment. The current study aims to
 evaluate whether the previously introduced, and now widely accepted and implemented
 educational program, which represents additional efforts in everyday practice to increase
 patient compliance, will succeed in achieving adherence rate in treated participants similar
 to the extent demonstrated by clinical trials.
Inclusion Criteria:

 -  Before inclusion, all participants must be informed and must give consent for the use
 of his/her anonymized health data related to his/her treatment with Peginterferon
 alfa-2b (injection pen) and Ribavirin.

 Exclusion Criteria:

 -  According to Peginterferon alfa-2b/Ribavirin label.